NCT03724968View on ClinicalTrials.gov

Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression

PHASE2TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

January 17, 2019

Primary Completion Date

May 28, 2020

Study Completion Date

May 28, 2020

Conditions
Metastatic MelanomaAdvanced MelanomaMetastatic Melanoma Stratified by MHC-II Expression
Interventions
DRUG

Nivolumab

Nivolumab will be given by vein on day 1 of each cycle.

DRUG

Relatlimab

Relatlimab will be given by vein on day 1 of each 28-day cycle

DRUG

Ipilimumab

Ipilimumab will be given by vein on day 1 during cycles 1-4 (cycles are 21 days).

Trial Locations (1)

37232

Vanderbilt-Ingram Cancer Center, Nashville

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Elizabeth Davis

OTHER

NCT03724968 - Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression | Biotech Hunter | Biotech Hunter